What is the fine-grained topic of the following text: Pentec was alleged to have routinely waived patient cost-sharing balances under Medicare's prescription drug benefit (Part D) in order to entice Medicare beneficiaries to use Proplete in connection with dialysis treatment, even though, as stated in the Complaint, Proplete was often substantially more expensive than drugs offered by Pentec's competitors. Only return the topic.
Pentec's alleged illegal waiving of patient cost-sharing balances under Medicare's Part D for dialysis treatment drugs